Position in EXEL
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$492,410
+$103,098 QoQ
Shares Held
9,050
-0.3% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#428
of 751 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Fifth Third Wealth Advisors LLC holds $7,687,403 across 13 Biotechnology names. EXEL ranks #4 (6.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
18,943 | $2,147,378 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,168 | $1,351,834 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,849 | $918,453 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
9,050 | $492,410 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
1,994 | $480,494 | |
| 6 | CYTK |
Cytokinetics Inc
|
5,154 | $439,069 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
1,109 | $412,182 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
10,744 | $380,230 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $492,410 | 9,050 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $389,312 | 9,077 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $383,249 | 8,744 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $361,044 | 8,742 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $391,254 | 8,876 | Shares | Sole | 2025-07-25 | |
| 2025-03-31 | $326,778 | 8,851 | Shares | Sole | 2025-04-08 | |
| 2024-12-31 | $293,739 | 8,821 | Shares | Sole | 2025-01-14 | |
| 2024-09-30 | $228,904 | 8,821 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $215,712 | 9,600 | Shares | Sole | 2024-07-23 | |
| No filing history on record for this holder in this stock. | ||||||